STRS Ohio’s Stemline Therapeutics, Inc. STML Stock Holding History

STRS Ohio’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-3,500	Closed	-$71K	–	1800
2014 Q1	$71K	Hold	3,500	–	–	﹤0.01%	1590
2013 Q4	$69K	Sell	3,500 -400	-10%	-$10.7K	﹤0.01%	1605
2013 Q3	$177K	Sell	3,900 -400	-9%	-$13K	﹤0.01%	1526
2013 Q2	$103K	Buy	+4,300	New	+$68.5K	﹤0.01%	1626

Other funds holding STML

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCA

Private Capital Advisors Darien, Connecticut $872M AUM 26.12% 1-Year Est. Return

STRS Ohio's STML Position: Q2 2014 in Review

STRS Ohio sold out of Stemline Therapeutics, Inc. (STML) in Q2 2014, closing a stake of 3,500 shares — an estimated $71K sold.

STRS Ohio first reported a position in STML in Q2 2013 and held it in 4 quarters. The position peaked at $177K in Q3 2013. 61 funds tracked by Wall St. Rank hold STML as of Q2 2014.

STRS Ohio reported no remaining Stemline Therapeutics, Inc. position as of Q2 2014 after selling out during the quarter.
STRS Ohio sold 3,500 Stemline Therapeutics, Inc. shares in Q2 2014, an estimated $71K.
STRS Ohio first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 4 quarters.
STRS Ohio's Stemline Therapeutics, Inc. position peaked at $177K in Q3 2013.
61 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2014.

Based on STRS Ohio's 13F filing for Q2 2014, filed 24 Jul 2014.